^
    Back
    Association details:
    Biomarker:CEBPA mutation
    Cancer:Acute Myelogenous Leukemia
    Regimen: (aclarubicin + cytarabine + decitabine + granulocyte-colony stimulating factor (GCSF))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    The Prognosis of Intermediate- and High-Risk Young AML Patients Who Did Not Receive Allo-HSCT Treated with Intensive Chemotherapy Is Not Superior to That of Elderly AML Patients Treated with the D-CAG Regimen

    Published date:
    11/04/2021
    Excerpt:
    The median age was 67 (range, 60 to 86 years) and 36 years (range, 14 to 59 years) in D-CAG and IA cohort, respectively...Individuals with biallelic CEBPA and NRAS mutations were more likely to benefit from intensive chemotherapy regimens.
    DOI:
    10.1182/blood-2021-149060